MCID: INT064
MIFTS: 51

Intermediate Uveitis

Categories: Eye diseases, Rare diseases

Aliases & Classifications for Intermediate Uveitis

MalaCards integrated aliases for Intermediate Uveitis:

Name: Intermediate Uveitis 12 56 14
Uveitis, Intermediate 42 69
Peripheral Uveoretinitis 12
Uveitis Intermediate 52
Chronic Cyclitis 12
Iu 56

Characteristics:

Orphanet epidemiological data:

56
intermediate uveitis
Inheritance: Not applicable; Age of onset: Childhood; Age of death: normal life expectancy;

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Eye diseases
Orphanet: 56  
Rare eye diseases


External Ids:

Disease Ontology 12 DOID:12732
MeSH 42 D015867
NCIt 47 C35110
Orphanet 56 ORPHA279914
UMLS via Orphanet 70 C0042166
ICD10 via Orphanet 34 H30.2
UMLS 69 C0042166

Summaries for Intermediate Uveitis

MalaCards based summary : Intermediate Uveitis, also known as uveitis, intermediate, is related to choroiditis and alopecia. An important gene associated with Intermediate Uveitis is IL2RA (Interleukin 2 Receptor Subunit Alpha), and among its related pathways/superpathways are ERK Signaling and PEDF Induced Signaling. The drugs Azathioprine and Chlorambucil have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and endothelial, and related phenotypes are cardiovascular system and cellular

Wikipedia : 72 Intermediate uveitis is a form of uveitis localized to the vitreous and peripheral retina. Primary sites... more...

Related Diseases for Intermediate Uveitis

Diseases in the Uveitis family:

Posterior Uveitis Intermediate Uveitis
Infectious Anterior Uveitis Anterior Uveitis
Infectious Posterior Uveitis

Diseases related to Intermediate Uveitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 322)
id Related Disease Score Top Affiliating Genes
1 choroiditis 29.2 IL10 IL6 TNF
2 alopecia 29.0 IL10 IL6 TNF
3 hepatitis b 28.8 IFNG IL10 IL2RA TNF
4 lymphoma 27.2 IFNG IL10 IL2 IL6 TNF
5 congenital disorder of glycosylation, type iu 12.0
6 pars planitis 11.9
7 rickets 11.3
8 epileptic encephalopathy, early infantile, 36 11.2
9 factor xi deficiency, autosomal recessive 10.8
10 uveitis 10.7
11 hypothyroidism due to deficient transcription factors involved in pituitary development or function 10.5 IFNG IL2RA
12 fibrous histiocytoma 10.5 IFNG IL2RA
13 mazabraud syndrome 10.5 HLA-B IFNG
14 acanthoma 10.4 HLA-B IFNG
15 thelaziasis 10.4 IFNG IL10
16 hemolytic anemia due to triosephosphate isomerase deficiency 10.4 CXCR3 IL2RA
17 dumping syndrome 10.4 IFNG IL10
18 crohn's colitis 10.4 IL2RA TNF
19 heterotaxy, visceral, 4, autosomal 10.4 HLA-B IL6
20 autoimmune retinopathy 10.4 IL2RA TNF
21 gerstmann syndrome 10.4 IFNG IL10
22 cranial nerve malignant neoplasm 10.4 CXCR3 IFNG
23 centronuclear myopathy 5 10.4 IFNG IL10
24 strawberry gallbladder 10.4 IFNG IL10
25 migraine with brainstem aura 10.4 HLA-B TNF
26 hemangioma of spleen 10.3 IFNG IL6
27 sternal cleft 10.3 IFNG TNF
28 tonsil cancer 10.3 IFNG IL10
29 mosaic trisomy 1 10.3 IFNG TNF
30 peroneal nerve paralysis 10.3 IL10 IL6
31 primary systemic mycosis 10.3 IFNG TNF
32 drug rash with eosinophilia and systemic symptoms 10.3 IL10 IL6
33 extrapulmonary tuberculosis 10.3 IL10 TGFBR3
34 not otherwise specified 3-mga-uria type 10.3 HLA-B TNF
35 infancy electroclinical syndrome 10.3 IL10 IL6
36 papillary squamous carcinoma 10.3 IFNG IL10
37 pure autonomic failure 10.3 IL10 TNF
38 anterior corneal pigmentation 10.3 HLA-B IL2RA TGFBR3
39 acute ackee fruit intoxication 10.2 IL10 TNF
40 smarca4-deficient sarcoma of thorax 10.2 IL6 TNF
41 aseptic meningitis 10.2 HLA-B TNF
42 aortic arch interruption 10.2 IL6 TNF
43 cutaneous leishmaniasis 10.2 IL6 TNF
44 multiple familial trichoepithelioma 10.2 IL10 TNF
45 polyarteritis nodosa 10.2 IFNG TNF
46 basidiobolomycosis 10.2 IL10 TNF
47 sparse hair ptosis mental retardation 10.2 IFNG TNF
48 lagophthalmos 10.2 IL10 TNF
49 type 1 papillary adenoma of the kidney 10.2 IL10 TNF
50 toxoplasmosis 10.2 IL6 TNF

Graphical network of the top 20 diseases related to Intermediate Uveitis:



Diseases related to Intermediate Uveitis

Symptoms & Phenotypes for Intermediate Uveitis

MGI Mouse Phenotypes related to Intermediate Uveitis:

44 (show all 12)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.05 IL6 TGFBR3 TNF CXCR3 IFNG IL10
2 cellular MP:0005384 10.04 TGFBR3 TNF CXCR3 IFNG IL10 IL2
3 hematopoietic system MP:0005397 10.03 IL2RA IL6 TGFBR3 TNF CXCR3 IFNG
4 immune system MP:0005387 10.01 CXCR3 IFNG IL10 IL2 IL2RA IL6
5 digestive/alimentary MP:0005381 9.95 IFNG IL10 IL2 IL2RA IL6 TNF
6 endocrine/exocrine gland MP:0005379 9.93 IFNG IL10 IL2 IL2RA IL6 TNF
7 mortality/aging MP:0010768 9.92 IL10 IL2 IL2RA IL6 TGFBR3 TNF
8 liver/biliary system MP:0005370 9.85 IFNG IL10 IL2 IL6 TGFBR3 TNF
9 neoplasm MP:0002006 9.73 CXCR3 IFNG IL10 IL2 IL6 TNF
10 reproductive system MP:0005389 9.63 IFNG IL10 IL2 IL6 TGFBR3 TNF
11 respiratory system MP:0005388 9.5 CXCR3 IFNG IL10 IL2 IL2RA IL6
12 vision/eye MP:0005391 9.1 IFNG IL10 IL2 IL2RA IL6 TNF

Drugs & Therapeutics for Intermediate Uveitis

Drugs for Intermediate Uveitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 105)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azathioprine Approved Phase 4 446-86-6 2265
2
Chlorambucil Approved Phase 4 305-03-3 2708
3
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
4
Daclizumab Approved, Investigational Phase 4,Phase 2,Phase 1 152923-56-3
5
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 67-73-2 6215
6
Infliximab Approved Phase 4,Phase 1,Phase 2 170277-31-3
7
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
8
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3 128794-94-5 5281078
9
Mycophenolic acid Approved Phase 4,Phase 3 24280-93-1 446541
10
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
11
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
12
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-02-2 5743
13 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
14 Antirheumatic Agents Phase 4,Phase 3,Phase 1,Phase 2
15 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
16 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
17 Hormones Phase 4,Phase 3,Phase 2,Phase 1
18 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
19 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
20 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Alkylating Agents Phase 4
22 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
23 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
24 Cyclosporins Phase 4,Phase 2
25 Adrenocorticotropic Hormone Phase 4,Phase 2
26 beta-endorphin Phase 4,Phase 2
27 Melanocyte-Stimulating Hormones Phase 4,Phase 2
28 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1
29 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
30 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
31 BB 1101 Phase 4,Phase 2,Phase 3,Phase 1
32 Dexamethasone acetate Phase 4,Phase 2,Phase 3,Phase 1 1177-87-3
33 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
34 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3
35
protease inhibitors Phase 4,Phase 2,Phase 3
36 Pharmaceutical Solutions Phase 4,Phase 3,Phase 1,Phase 2
37 Gramicidin Phase 4
38 Ophthalmic Solutions Phase 4
39 Polymyxin B Phase 4
40 Polymyxins Phase 4
41
Triamcinolone Approved, Vet_approved Phase 3,Phase 1,Phase 2 124-94-7 31307
42
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
43
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
44
Adalimumab Approved Phase 3,Phase 2 331731-18-1 16219006
45
Difluprednate Approved Phase 3 23674-86-4 443936
46
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2 59-30-3 6037
47
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
48 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
49 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
50 Anti-Infective Agents Phase 3,Phase 1,Phase 2

Interventional clinical trials:

(show top 50) (show all 76)

id Name Status NCT ID Phase Drugs
1 Multicenter Uveitis Steroid Treatment (MUST) Trial Completed NCT00132691 Phase 4 fluocinolone acetonide intraocular implant;oral corticosteroid with immunosuppressive agents as needed
2 Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients Completed NCT02764697 Phase 4 H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
3 Study of the Effectiveness of Ozurdex for the Control of Uveitis Recruiting NCT02049476 Phase 4 Dexamethasone pellet
4 Frozen Versus Fresh Corneal Carriers for the Boston KPro Type I Donor Carriers Enrolling by invitation NCT01950598 Phase 4
5 Myfortic for the Treatment of Non-infectious Intermediate Uveitis Completed NCT01092533 Phase 3 Myfortic;Decortin
6 Randomized, Controlled Trial to Test the Efficacy of Interferon Beta in the Treatment of Intermediate Uveitis Completed NCT00344253 Phase 3 Interferon beta;Methotrexate
7 Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis Completed NCT01124838 Phase 3 Adalimumab;Prednisone;Placebo
8 A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis Completed NCT00333814 Phase 2, Phase 3 Dexamethasone;dexamethasone;Sham injection
9 Efficacy and Safety of Adalimumab in Patients With Active Uveitis Completed NCT01138657 Phase 3 Prednisone;Placebo
10 Phase III Study in Refractory Behcet's Disease Completed NCT00995709 Phase 3 AIN457;AIN457;Placebo
11 A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis Completed NCT00404742 Phase 3 Placebo;LX211;LX211;LX211
12 A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis Completed NCT00404612 Phase 3 Placebo;LX211;LX211;LX211
13 Difluprednate Pediatric Study for the Treatment of Inflammation Post-Cataract Surgery Completed NCT01124045 Phase 3 Difluprednate ophthalmic emulsion, 0.05%;Prednisolone acetate ophthalmic suspension, 1.0%
14 Efficacy and Safety of Voclosporin to Treat Active Noninfectious Uveitis Completed NCT01243983 Phase 3 LX211
15 Study of Difluprednate Ophthalmic Emulsion in the Treatment of Severe Uveitis Completed NCT00407056 Phase 3 Difluprednate Ophthalmic Emulsion
16 Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis Completed NCT00406887 Phase 3 Difluprednate Ophthalmic Emulsion
17 Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal (FAI) Insert in Subjects With Chronic Non-infectious Posterior Uveitis Active, not recruiting NCT02746991 Phase 3 Sham Injection;FAI Insert
18 Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert Active, not recruiting NCT01694186 Phase 3 FAI insert;Sham injection
19 A Controlled, Multi-center Study of the Utilization and Safety of the MK II Inserter and the Safety of the FAI Insert in Subjects With Non-infectious Uveitis Affecting the Posterior Segment of the Eye Active, not recruiting NCT02748512 Phase 3 FAI insert
20 A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis Active, not recruiting NCT01148225 Phase 3 adalimumab
21 Suprachoroidal Injection of CLS-TA in Subjects Non-infectious Uveitis Active, not recruiting NCT03097315 Phase 3
22 Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis Active, not recruiting NCT02595398 Phase 3 4mg CLS-TA Suprachoriodal Injection;Sham Procedure
23 Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis Terminated NCT01032915 Phase 3 Placebo
24 Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis Terminated NCT01095250 Phase 3 AIN457;AIN457;AIN457;Placebo
25 38 Week Extension Study to CAIN457C2303 Terminated NCT01093846 Phase 3 AIN457;AIN457;Placebo AIN457
26 Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis Terminated NCT01684345 Phase 3 Placebo;Dose 1 gevokizumab;Dose 2 gevokizumab
27 Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis Terminated NCT01103024 Phase 3
28 Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic Treatment Terminated NCT01747538 Phase 3 Placebo;Dose 1 gevokizumab;Dose 2 gevokizumab
29 Long-term Safety of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis (EYEGUARD-X) Terminated NCT02375685 Phase 3
30 Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis Terminated NCT01090310 Phase 3 AIN457;Placebo
31 An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data Terminated NCT02258854 Phase 3 Dose 2 gevokizumab
32 Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implant Terminated NCT00456482 Phase 2, Phase 3 Fluocinolone Acetonide 0.59mg;Fluocinolone Acetonide 2.1mg
33 Study to Evaluate the Long Term Use of Treatment With AIN457 for Uveitis Withdrawn NCT01327664 Phase 3
34 Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis Completed NCT00615693 Phase 2 AEB071
35 Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis , Completed NCT01526889 Phase 2 LFG316;Conventional Therapy
36 Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis Completed NCT01789320 Phase 1, Phase 2 triamcinolone acetonide (Triesence®)
37 Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis Completed NCT01582880 Phase 1, Phase 2 Riboflavin
38 Topical Interferon Gamma for Macular Edema Secondary to Uveitis Completed NCT01376362 Phase 1, Phase 2 Interferon Gamma-1b
39 Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis Completed NCT02255032 Phase 2 4 mg CLS-TA;0.8 mg CLS-TA
40 Intravitreal Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical Study Completed NCT02620618 Phase 1, Phase 2 Intravitreal Infliximab
41 Safety and Efficacy of AIN457 in Noninfectious Uveitis Completed NCT00685399 Phase 2 AIN457;AIN 457;AIN457
42 Leflunomide to Treat Uveitis Completed NCT00001863 Phase 2 Leflunomide
43 Combination Daclizumab/Denileukin Diftitox to Treat Uveitis Completed NCT00326508 Phase 2 Daclizumab
44 Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis Completed NCT01900431 Phase 2 Sarilumab;Prednisone;Methotrexate;Folic/folinic acid
45 Everolimus for the Treatment of Uveitis Unresponsive to Cyclosporine A Completed NCT00803816 Phase 2 everolimus
46 Intravitreal Sirolimus as Therapeutic Approach to Uveitis Recruiting NCT01280669 Phase 2 Intravitreal injection 440mcg;Intravitreal injection of sirolimus 880mcg
47 Ustekinumab (STELARA ) for the Treatment of Active Sight-Threatening Uveitis Recruiting NCT02911116 Phase 2 Ustekinumab
48 Vision Restoration With a Collagen Crosslinked Boston Keratoprosthesis Unit Recruiting NCT02863809 Phase 1, Phase 2 Riboflavin;Dextran
49 Evaluation of EYS606 in Patients With Non-infectious Posterior, Intermediate or Panuveitis Recruiting NCT03308045 Phase 1, Phase 2
50 Intravitreal Adalimumab Versus Subcutaneous Adalimumab in Non-infectious Uveitis Recruiting NCT02706704 Phase 2 Adalimumab

Search NIH Clinical Center for Intermediate Uveitis

Cochrane evidence based reviews: uveitis, intermediate

Genetic Tests for Intermediate Uveitis

Anatomical Context for Intermediate Uveitis

MalaCards organs/tissues related to Intermediate Uveitis:

39
Eye, Retina, Endothelial, Testes, T Cells, B Cells

Publications for Intermediate Uveitis

Articles related to Intermediate Uveitis:

(show top 50) (show all 165)
id Title Authors Year
1
PERIPHERAL RETINOSCHISIS IN INTERMEDIATE UVEITIS. ( 28590967 )
2017
2
Re: Jaffe etA al.: Injectable fluocinolone acetonide long-acting implant for noninfectious intermediate uveitis, posterior uveitis, and panuveitis: 2-year results (Ophthalmology. 2016;123:1940-1948). ( 28734339 )
2017
3
Re: Jaffe etA al.: Injectable fluocinolone acetonide long-acting implant for noninfectious intermediate uveitis, posterior uveitis, and panuveitis: two-year results (Ophthalmology. 2016;123:1940-1948). ( 28335961 )
2017
4
Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials. ( 28426849 )
2017
5
Preoperative Inflammatory Control and Surgical Outcome of Vitrectomy in Intermediate Uveitis. ( 28465834 )
2017
6
Listeria Monocytogenes Endophthalmitis after Intermediate Uveitis and ppV for Retinal Detachment. ( 28329887 )
2017
7
Re: Niederer etA al.: Predictors of long-term visual outcome in intermediate uveitis (Ophthalmology. 2017;124:393-398). ( 28645347 )
2017
8
Long-term results of pars plana vitrectomy as an anti-inflammatory therapy of pediatric intermediate uveitis resistant to standard medical treatment. ( 28862736 )
2017
9
Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. ( 28903965 )
2017
10
Cystoid Macular Edema in Retinitis Pigmentosa with Intermediate Uveitis Responded Well to Oral and Posterior Subtenon Steroid. ( 28353369 )
2017
11
Intermediate uveitis: pattern of etiology, complications, treatment and outcome in a tertiary academic center. ( 28449695 )
2017
12
Association between intermediate uveitis and toxocariasis in the Korean population. ( 28151857 )
2017
13
Patterns of Intermediate Uveitis in Children Presenting at a Tertiary Eye Care Center in South India. ( 28936054 )
2017
14
INTERMEDIATE UVEITIS ASSOCIATED WITH PERIODIC FEVER, APHTHOUS STOMATITIS, PHARYNGITIS, AND CERVICAL ADENITIS SYNDROME. ( 28570435 )
2017
15
Bilateral intermediate uveitis with appearance of frosted branch angiitis and associated with Mycoplasma pneumoniae infection: case report and review of the literature. ( 27132140 )
2016
16
Influence of baseline demographic and clinical characteristics in the visual outcome of intermediate uveitis: a survival analysis. ( 27030281 )
2016
17
Remission of Intermediate Uveitis: Incidence and Predictive Factors. ( 26772874 )
2016
18
Ultra-wide Field Fluorescein Angiography in Retinitis Pigmentosa with Intermediate Uveitis. ( 27413510 )
2016
19
Associations of Systemic Diseases with Intermediate Uveitis. ( 26786193 )
2016
20
Phenotypic changes of peripheral blood mononuclear cells upon corticosteroid treatment in idiopathic intermediate uveitis. ( 27989897 )
2016
21
Ocular Siderosis Subsequent to a Missed Pars Plana Metallic Foreign Body that Masqueraded as Refractory Intermediate Uveitis. ( 27849408 )
2016
22
A cross-sectional study of submacular thickening in intermediate uveitis and determination of treatment threshold. ( 27188332 )
2016
23
Chikungunya Virus Infection Manifesting as Intermediate Uveitis. ( 28010143 )
2016
24
Predictors of Long-Term Visual Outcome in Intermediate Uveitis. ( 28017424 )
2016
25
Peripheral Vasculitis, Intermediate Uveitis and Interferon Use in Multiple Sclerosis. ( 27800257 )
2016
26
Injectable Fluocinolone Acetonide Long-Acting Implant for Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Two-Year Results. ( 27421623 )
2016
27
Risk of Ocular Complications in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. ( 26712559 )
2016
28
Retinal Dystrophy in 6 Young Patients Who Presented with Intermediate Uveitis. ( 27157150 )
2016
29
Use of Immunosuppressive Medications for Treatment of Pediatric Intermediate Uveitis. ( 27960602 )
2016
30
INFLIXIMAB THERAPY IN PATIENTS WITH NONINFECTIOUS INTERMEDIATE UVEITIS RESISTANT TO CONVENTIONAL IMMUNOMODULATORY THERAPY. ( 27681002 )
2016
31
Quality of Life and Risks Associated with Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, or Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment Trial and Follow-up Study. ( 26298718 )
2015
32
Possession of the HLA-DRB1*1501 Allele and Visual Outcome in Idiopathic Intermediate Uveitis. ( 25634309 )
2015
33
Intermediate uveitis: an unusual presentation of cytomegalovirus intraocular infection in an immunocompetent patient. ( 25969485 )
2015
34
Clinical characteristics of intermediate uveitis in adult Turkish patients. ( 26309876 )
2015
35
Chronic candida endophthalmitis as a cause of intermediate uveitis. ( 25870216 )
2015
36
Association analysis of TGFBR3 gene with BehAset's disease and idiopathic intermediate uveitis in a Caucasian population. ( 25677673 )
2015
37
Intermediate uveitis and multiple sclerosis: to scan or not to scan. ( 26338960 )
2015
38
Intermediate uveitis, posterior uveitis, and panuveitis in the Mid-Atlantic USA. ( 26345421 )
2015
39
Associations of Independent IL2RA Gene Variants with Intermediate Uveitis. ( 26133380 )
2015
40
Analysis of a Functional IL-6 Gene Polymorphism in HLAB27 Associated and Intermediate Uveitis Gives New Insight in Disease Pathogenesis and Commonality with Other Autoimmune Diseases. ( 26640809 )
2015
41
A case of multiple sclerosis with bilateral intermediate uveitis. ( 26289756 )
2015
42
Treatment of cystoid macular edema secondary to chronic non-infectious intermediate uveitis with an intraocular dexamethasone implant. ( 26222112 )
2015
43
Efficacy of Ozurdex implant in treatment of noninfectious intermediate uveitis. ( 26655000 )
2015
44
Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study. ( 26298715 )
2015
45
Discrepancy in Fluorescein Angiography and Optical Coherence Tomography Findings of Macular Edema in Intermediate Uveitis. ( 26645484 )
2015
46
Anterior and Intermediate Uveitis with Retinal Vasculitis: An Unusual Manifestation of Post-Streptococcal Uveitis Syndrome. ( 26713592 )
2015
47
Intermediate uveitis associated with familial Mediterranean fever. ( 26487035 )
2015
48
Retinal and choroidal thickness measurements using spectral domain optical coherence tomography in anterior and intermediate uveitis. ( 25176513 )
2014
49
Trends in patterns of intermediate uveitis in a tertiary institution in Singapore. ( 24626440 )
2014
50
Intermediate uveitis in children and young adults: differences in clinical course, associations and visual outcome. ( 24713505 )
2014

Variations for Intermediate Uveitis

Expression for Intermediate Uveitis

Search GEO for disease gene expression data for Intermediate Uveitis.

Pathways for Intermediate Uveitis

Pathways related to Intermediate Uveitis according to GeneCards Suite gene sharing:

(show top 50) (show all 67)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.73 CXCR3 IL10 IL2 IL2RA IL6 TGFBR3
2
Show member pathways
13.57 CXCR3 IFNG IL10 IL2 IL2RA IL6
3
Show member pathways
13.45 IFNG IL10 IL2 IL2RA IL6 TGFBR3
4
Show member pathways
13.32 CXCR3 IL10 IL2 IL2RA IL6 TNF
5
Show member pathways
13.28 HLA-B IFNG IL10 IL2 IL2RA IL6
6
Show member pathways
13.22 CXCR3 IL10 IL2 IL2RA IL6 TGFBR3
7
Show member pathways
12.84 IFNG IL10 IL2 IL6 TNF
8
Show member pathways
12.74 HLA-B IFNG IL2 IL2RA IL6 TNF
9
Show member pathways
12.71 IL2 IL2RA IL6 TNF
10
Show member pathways
12.69 HLA-B IFNG IL10 IL2 IL2RA IL6
11 12.62 HLA-B IL2 IL2RA IL6 TNF
12
Show member pathways
12.61 IFNG IL10 IL2 IL2RA TNF
13
Show member pathways
12.56 IFNG IL10 IL2 IL6 TNF
14 12.52 IFNG IL10 IL2 IL2RA TNF
15
Show member pathways
12.49 IFNG IL10 IL2 IL2RA IL6 TNF
16
Show member pathways
12.48 HLA-B IFNG IL2 TNF
17
Show member pathways
12.41 IFNG IL10 IL2 IL6 TNF
18 12.4 HLA-B IL2 IL2RA IL6 TNF
19
Show member pathways
12.25 IFNG IL6 TNF
20 12.22 HLA-B IFNG IL10
21 12.22 IFNG IL10 IL6 TNF
22
Show member pathways
12.2 IFNG IL6 TNF
23
Show member pathways
12.18 IFNG IL10 TNF
24
Show member pathways
12.17 IFNG IL10 IL2 IL2RA IL6
25
Show member pathways
12.12 IFNG IL6 TNF
26 12.12 IFNG IL6 TNF
27 12.11 IL10 IL6 TNF
28
Show member pathways
12.02 IFNG IL2 IL2RA
29 12.02 IFNG IL2 IL6 TNF
30
Show member pathways
12.01 HLA-B IFNG IL10 IL2 IL6 TNF
31 11.95 IL10 IL6 TNF
32
Show member pathways
11.94 IFNG IL2 IL2RA
33 11.9 IFNG IL10 IL6 TNF
34
Show member pathways
11.89 IFNG IL6 TGFBR3
35 11.87 IL2RA IL6 TNF
36
Show member pathways
11.86 IFNG IL10 IL2 IL6 TNF
37 11.84 IFNG IL6 TNF
38 11.84 IFNG IL10 IL2 IL2RA IL6
39 11.8 IFNG IL10 IL2 IL2RA IL6 TNF
40 11.79 IFNG IL2 IL6
41
Show member pathways
11.77 IFNG IL2 IL2RA TNF
42 11.75 IL10 IL6 TNF
43 11.73 IL10 IL2RA IL6 TNF
44
Show member pathways
11.67 IFNG IL2 IL6 TNF
45 11.65 IFNG IL10 IL2 IL6 TNF
46
Show member pathways
11.64 IFNG IL2 IL2RA TNF
47 11.63 IFNG TGFBR3 TNF
48 11.56 IFNG IL2 IL6 TNF
49 11.55 IL10 IL6 TNF
50 11.54 IFNG IL2 TNF

GO Terms for Intermediate Uveitis

Cellular components related to Intermediate Uveitis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 IFNG IL10 IL2 IL6 TGFBR3 TNF
2 extracellular space GO:0005615 9.63 IFNG IL10 IL2 IL6 TGFBR3 TNF
3 cell surface GO:0009986 9.35 CXCR3 HLA-B IL2RA TGFBR3 TNF
4 external side of plasma membrane GO:0009897 9.1 CXCR3 IFNG IL2RA IL6 TGFBR3 TNF

Biological processes related to Intermediate Uveitis according to GeneCards Suite gene sharing:

(show all 44)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.98 IFNG IL10 IL6 TNF
2 defense response to bacterium GO:0042742 9.87 IFNG IL10 TNF
3 positive regulation of protein phosphorylation GO:0001934 9.84 IFNG IL2 TNF
4 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.8 IL10 IL6 TNF
5 negative regulation of inflammatory response GO:0050728 9.77 IL10 IL2 IL2RA
6 inflammatory response GO:0006954 9.77 CXCR3 IL10 IL2RA IL6 TNF
7 response to glucocorticoid GO:0051384 9.72 IL10 IL6 TNF
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.71 IFNG IL2 IL6
9 humoral immune response GO:0006959 9.7 IFNG IL6 TNF
10 negative regulation of mitotic cell cycle GO:0045930 9.69 IL10 TNF
11 positive regulation of activated T cell proliferation GO:0042104 9.69 IL2 IL2RA
12 positive regulation of cytokine secretion GO:0050715 9.68 IL10 TNF
13 protein import into nucleus, translocation GO:0000060 9.68 IFNG TNF
14 negative regulation of interleukin-6 production GO:0032715 9.68 IL10 TNF
15 positive regulation of protein complex assembly GO:0031334 9.67 IFNG TNF
16 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.67 IL10 TNF
17 positive regulation of osteoclast differentiation GO:0045672 9.67 IFNG TNF
18 positive regulation of T cell differentiation GO:0045582 9.66 IL2 IL2RA
19 positive regulation of chemokine production GO:0032722 9.65 IL6 TNF
20 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.65 IFNG TNF
21 cellular response to hepatocyte growth factor stimulus GO:0035729 9.64 IL10 IL6
22 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.64 IL10 TNF
23 positive regulation of immunoglobulin secretion GO:0051024 9.63 IL2 IL6
24 positive regulation of protein import into nucleus, translocation GO:0033160 9.63 IFNG IL6
25 positive regulation of isotype switching to IgG isotypes GO:0048304 9.62 IFNG IL2
26 cellular response to lipopolysaccharide GO:0071222 9.62 IFNG IL10 IL6 TNF
27 positive regulation of chemokine biosynthetic process GO:0045080 9.61 IFNG TNF
28 negative regulation of lipid storage GO:0010888 9.61 IL6 TNF
29 positive regulation of nitric oxide biosynthetic process GO:0045429 9.61 IFNG IL6 TNF
30 endothelial cell apoptotic process GO:0072577 9.59 IL10 TNF
31 positive regulation of MHC class II biosynthetic process GO:0045348 9.58 IFNG IL10
32 negative regulation of lymphocyte proliferation GO:0050672 9.58 IL2 IL2RA
33 negative regulation of cytokine secretion involved in immune response GO:0002740 9.57 IL10 TNF
34 epithelial cell proliferation involved in salivary gland morphogenesis GO:0060664 9.56 IL6 TNF
35 receptor biosynthetic process GO:0032800 9.51 IL10 TNF
36 regulation of T cell homeostatic proliferation GO:0046013 9.49 IL2 IL2RA
37 neutrophil apoptotic process GO:0001781 9.48 IFNG IL6
38 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.46 IFNG TNF
39 defense response to protozoan GO:0042832 9.43 IFNG IL10 IL6
40 positive regulation of vitamin D biosynthetic process GO:0060557 9.4 IFNG TNF
41 negative regulation of growth of symbiont in host GO:0044130 9.33 IFNG IL10 TNF
42 positive regulation of T cell proliferation GO:0042102 9.26 IFNG IL2 IL2RA IL6
43 immune response GO:0006955 9.23 HLA-B IFNG IL10 IL2 IL2RA IL6
44 positive regulation of transcription from RNA polymerase II promoter GO:0045944 10.05 IFNG IL10 IL2 IL6 TNF

Molecular functions related to Intermediate Uveitis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.13 IL10 IL2 IL6
2 cytokine activity GO:0005125 9.02 IFNG IL10 IL2 IL6 TNF

Sources for Intermediate Uveitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....